Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
a biotechnology company dedicated to the development of novel
neuroplastogenic small-molecule therapeutics for the treatment of
depression, anxiety, and addiction disorders, today announced the
presentation of two posters at the Canadian Chemical Engineering
Conference (CSChE 2023) which was held October 29th to November 1,
2023.
The first poster entitled, “Biocatalytic production of MDMA and
other phenylpropylamine derivatives,” presented an alternative
process for MDMA production integrating yeast-based bioconversion
and biocatalytic steps. First, the Enveric research team achieved
the production of milligram quantities of pure compounds in
small-scale batch fermentations. The second step of MDMA
bioproduction involved transamination and was achieved using a
biocatalytic approach, which proved to be more efficient compared
with yeast-based conversion. The purified transamination products
were converted to methamphetamine derivatives, including MDMA, by
chemical reduction and N-methylation.
The second poster entitled, “A synthetic biology platform for
the production of novel indolethylamine derivatives as drug
candidates to treat anxiety and depression,” presented
bioproduction platforms, which offer an emerging alternative to
traditional chemical synthesis of psychedelic-inspired molecules
with a reduced hallucinogenic potential and sustained therapeutic
benefits. The presentation described a collection of biosynthetic
tools, including known and previously unidentified biocatalysts,
enabling the production of >350 indolethylamine derivatives from
simple indolic precursors. Collections of enzymes with known
activities including tryptophan synthases, tryptophan
decarboxylases (TDCs), halogenases, prenyltransferases,
hydroxylases, kinases, N-acetyltransferases, and
N-methyltransferases were screened for performance in E. coli and
for substrate promiscuity. Using the synthetic biology platform,
Enveric researchers were able to produce several previously
undescribed, wholly novel products with important activities at
target receptors.
“Our team’s presentations showcased the advantages of using
metabolic engineering over synthetic chemistry to provide
biosynthesis in fewer steps, avoiding complex, multi-step
procedures to produce compounds with emerging potential as
treatments for mental health disorders like MDMA and psilocybin,
and importantly derivatives of these compounds,” said Joseph
Tucker, Ph.D., Director and CEO of Enveric. “We were pleased to
further demonstrate our team’s innovative work to bring novel
methods to the production of New Chemical Entities as we continue
to analyze psychedelic and psychedelic-inspired compounds for their
potential as improved treatments for mental health conditions,
including depression, anxiety, and addiction disorders.”
Details of the presentations are as follows:
Title: Biocatalytic production of MDMA and other
phenylpropylamine derivatives Presenter: Dr. Natali Ozber
Symposium: Biotechnology, Biochemical, and Biomedical Engineering
Poster presentation on Monday October 30, 2023
Title: A synthetic biology platform for the production of novel
indolethylamine derivatives as drug candidates to treat anxiety and
depression Presenter: Dr. Jillian Hagel Symposium: Biotechnology,
Biochemical, and Biomedical Engineering Poster presentation on
November 1, 2023
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company
dedicated to the development of novel neuroplastogenic
small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging its unique discovery
and development platform, Psybrary™, Enveric has created a robust
intellectual property portfolio of New Chemical Entities for
specific mental health indications. Enveric’s lead program, the
EVM201 Series, comprises next generation synthetic prodrugs of the
active metabolite, psilocin. Enveric is developing the first
product from the EVM201 Series – EB-373 – for the treatment of
psychiatric disorders. Enveric is also advancing its second
program, the EVM301 Series, expected to offer a first-in-class, new
approach to the treatment of difficult-to-address mental health
disorders, mediated by the promotion of neuroplasticity without
also inducing hallucinations in the patient. Enveric is
headquartered in Naples, FL with offices in Cambridge, MA and
Calgary, AB Canada. For more information, please visit
www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as “plans,” “expects” or
“does not expect,” “proposed,” “is expected,” “budgets,”
“scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or
“does not anticipate,” or “believes,” or variations of such words
and phrases, or by the use of words or phrases which state that
certain actions, events or results may, could, would, or might
occur or be achieved. Forward-looking statements may include
historical statements and statements regarding beliefs, plans,
expectations, or intentions regarding the future and are based on
the beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including, but not
limited to, the ability of Enveric to: carry out successful
clinical programs in Australia; achieve the value creation
contemplated by technical developments; avoid delays in planned
clinical trials; establish that potential products are efficacious
or safe in preclinical or clinical trials; establish or maintain
collaborations for the development of therapeutic candidates;
obtain appropriate or necessary governmental approvals to market
potential products; obtain future funding for product development
and working capital on commercially reasonable terms; scale-up
manufacture of product candidates; respond to changes in the size
and nature of competitors; hire and retain key executives and
scientists; secure and enforce legal rights related to Enveric’s
products, including patent protection; identify and pursue
alternative routes to capture value from its cannabinoid clinical
development pipeline assets; continue as a going concern; and
manage its future growth effectively.
A discussion of these and other factors, including risks and
uncertainties with respect to Enveric, is set forth in Enveric’s
filings with the Securities and Exchange Commission, including
Enveric’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Enveric disclaims any intention or obligation to revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231123642251/en/
Investor Relations Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng (862) 213-1398
dboateng@tiberend.com
Media Relations Tiberend Strategic Advisors, Inc. Casey
McDonald (646) 577-8520 cmcdonald@tiberend.com
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From Apr 2024 to May 2024
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From May 2023 to May 2024